Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Integration of Immuno-Oncology into Contemporary Management of Muscle-invasive Urothelial Carcinoma
June 2024
At the European Association of Urology (EAU) 2024 Conference, Jürgen Gschwend (Department of Urology, Hopital Rechts der Isar Technical…
Read more
6th December 2022
Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape
Chaired by Prof. Andrea Necchi, this symposium presented by Prof. Rouprêt and Prof. Retz explores the treatment landscape for muscle-invasive urothelial carcinoma, as well as their perspectives on future treatment landscape.
1st December 2022
Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine
Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).
25th November 2022
Dilemmas in breast cancer treatment planning: how understanding tumor biology with MammaPrint and BluePrint can help you
This webinar will educate you on how the biology of a breast tumour reveals additional information that can support choosing the best treatment plan. It will specifically focus on now-a-days clinical dilemmas, like what is the best treatment for pre-menopausal patients, what is the optimal duration of endocrine therapy and how can I find those nasty tumours. The dilemmas are discussed with the help of cases.
18th November 2022
BRAF V600E Mutant Metastatic Colorectal Cancer: New Treatment Options and Future Perspectives
Watch this webinar on BRAF V600E mutant metastatic colorectal cancer (mCRC), chaired by therapeutic leaders in the field Professor Fortunato Ciardiello and Professor Chaira Cremolini.
11th November 2022
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL
Not able to attend the Expert Roundtable Discussion in Paris? Access the on-demand webcast here. This interactive event features expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Topics include:
8th November 2022
Prosigna on demand webinars
Interactive webinar designed for doctors treating breast cancer interested in advancing personalized treatment through molecular gene expression testing.
4th November 2022
From Clinical Trial to Real-World Evidence: Everyday Practice with
MET
ex14 Inhibitors in NSCLC
This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).
26th October 2022
Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment
The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.
Loading posts...
« Previous
1
2
3
4
5
6
…
46
Next »